Evidence map›Paper›PMID 21610144›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma.

Audrey Vincent, Noriyuki Omura, Seung-Mo Hong, Andrew Jaffe, James Eshleman, Michael Goggins

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 2 syntheses or guidelines pooled it, 181 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Audrey VincentDepartment of Pathology, Oncology, and Medicine, Bloomberg School of Public Health, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, Maryland, USA.
Noriyuki Omura
Seung-Mo Hong
Andrew Jaffe
James Eshleman
Michael Goggins
Cancer Research Center · USJohns Hopkins University · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
Predicting pancreatic cancer responses for a Parp inhibitor-based clinical trialRC2CA148346 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2009 to 2010
$1.9M
Markers of Early Pancreatic CancerR01CA120432 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2006 to 2010
$1.4M
Novel Human Cancer Cell Isolation SystemR01CA130938 · NCI · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, JAMES R. · 2008 to 2011
$1.2M
NCI NIH HHS CA120432NCI NIH HHS CA62924NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA120432NCI NIH HHS R01 CA130938NCI NIH HHS RC2 CA148346NCI NIH HHS RC2CA148346
6 · The paper itself

Abstract

purposeThe goal of this study was to comprehensively identify CpG island methylation alterations between pancreatic cancers and normal pancreata and their associated gene expression alterations. EXPERIMENTAL

designWe employed methylated CpG island amplification followed by CpG island microarray, a method previously validated for its accuracy and reproducibility, to analyze the methylation profile of 27,800 CpG islands covering 21 MB of the human genome in nine pairs of pancreatic cancer versus normal pancreatic epithelial tissues and in three matched pairs of pancreatic cancer versus lymphoid tissues from the same individual.

resultsThis analysis identified 1,658 known loci that were commonly differentially methylated in pancreatic cancer compared with normal pancreas. By integrating the pancreatic DNA methylation status with the gene expression profiles of the same samples before and after treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine, and the histone deacetylase inhibitor, trichostatin A, we identified dozens of aberrantly methylated and differentially expressed genes in pancreatic cancers including a more comprehensive list of hypermethylated and silenced genes that have not been previously described as targets for aberrant methylation in cancer.

conclusionWe expected that the identification of aberrantly hypermethylated and silenced genes will have diagnostic, prognostic, and therapeutic applications.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticGenome-Wide Association StudyPromoter Regions, GeneticAdenocarcinomaCell AdhesionCell Line, TumorCpG IslandsDNA MethylationEpigenomicsGenetic LociHumansMultigene FamilyPancreatic NeoplasmsPluripotent Stem CellsSignal TransductionWnt Proteins

Identifiers

PMID21610144
PMCPMC3131423
OpenAlexW2132601639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.